Circulation-Heart Failure

Article	Citations
Cognitive and Procedural Competencies in the Cardiac Intensive Care Unit	128
GDMT Optimization, But Make It Patient-Centered: Understanding Patient Needs During Heart Failure Medication Discussions	126
Letter by Qiu and Du Regarding Article, “Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”	112
National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later	110
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection Fraction	101
Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure	85
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy	80
Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System	76
Advanced Life Support Medications in eCPR and the Limits of Causal Inference	64
Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance	60
Epicardial Fat Paradox and Differential Effects of GLP-1 Receptor Agonists Across Heart Failure Phenotypes	60
Longitudinal Trends in Donor and Recipient Risk Profile, and Clinical Outcomes, for Donation After Circulatory Death Heart Transplantation	55
Response by Myte et al to Letter Regarding Article, “Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin”	53
Characteristics of United States Counties in Which Heart Failure Clinical Trials of Pharmacotherapy Were Conducted	52
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program	50
High-Dose Versus Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial	47
Infarct Size Reduction With Cyclosporine A in Circulatory Death Rat Hearts: Reducing Effective Ischemia Time With Therapy During Reperfusion	45
Myosin ATPase Inhibition Relieves the Energetic Burden in Skeletal Myofibres of Patients With Heart Failure With Reduced Ejection Fraction	45
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group	45
Ongoing Enigma of NT-proBNP in HFpEF: Insights From Proteomics	44
Health-Related Quality of Life in Older Patients With Heart Failure From Before to Early After Advanced Surgical Therapies: Findings From the SUSTAIN-IT Study	44
Pseudo-Severe Mitral Stenosis From Obesity-Related HFpEF and Atrial Myopathy	44
Rethinking Donor and Recipient Risk Matching in Europe and North America: Using Heart Transplant Predictors of Donor and Recipient Risk	43
Long-Term Functional Outcomes in the First 12 Months After VA-ECMO in Adult Patients: A Prospective, Multicenter Study	41
Trajectory of Cognitive Function After Incident Heart Failure	40

Mechanisms Behind Dyspnea in Preload Insufficiency	39
Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock	38
Predicting 1-Year Mortality in Outpatients With Heart Failure With Reduced Left Ventricular Ejection Fraction: Do Empiric Models Outperform Physician Intuitive Estimates? A Multicenter Cohort Study	38
Letter by Baldovino et al Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”	37
Rethinking the Nomenclature of Heart Failure Cardiogenic Shock: Do We Need to Start De Novo?	36
Failing to Make the Grade: Conventional Cardiac Allograft Rejection Grading Criteria Are Inadequate for Predicting Rejection Severity	35
Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death	34
Increased Chamber Resting Tone Is a Key Determinant of Left Ventricular Diastolic Dysfunction	34
Expanding the Lens on Heart Failure Risk Stratification	34
Predicted Heart Mass: A Tale of 2 Ventricles	33
Real-Time Biventricular Pressure-Volume Loops During Percutaneous Pulmonary Valve Implantation in Patients With RVOT Dysfunction	33
Incidence and Outcomes of Advanced Heart Failure in Adults With Congenital Heart Disease	32
Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications	32
Current Approach to the Diagnosis of Sarcopenia in Heart Failure: A Narrative Review on the Role of Clinical and Imaging Assessments	31
Prolonged Extreme Asymptomatic Hypertroponinemia as a Milestone in Diagnosis of Familial Arrhythmogenic Right Ventricular Cardiomyopathy	31
Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury	30
Hierarchical Analysis of Composite Time-to-Event End Points in Heart Failure Clinical Trials Using Time in Clinical State	30
Pressure Overload–Induced Cardiac Hypertrophy Stimulates Tumor Growth in Tumor-Prone Apc Min Mice	30
Short-Term Effects of Ambient Temperature on Acute Heart Failure Decompensation: Phenotype-Specific Risk in a Time-Stratified Case-Crossover Study	30
Easing the Strain: Atrial Function After Atrial Shunting	30
Knowing All the Angles (on Right Ventricular Myocardial Remodeling)	30
Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure	29
Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation	29
Peripheral Venous Pressure+Fenestration Doppler=Noninvasive Cardiac Catheterization Post-Fontan	29
Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?	29
Letter by Hu Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”	29
Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1	29
Response by Prisco and Prins to Letter Regarding Article, “Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventri	28
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis	27
When the Whole Is the Sum of Its Parts: Validation of the Heart Failure Collaboratory Medication Composite Score in Denmark	27
Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction	26
Response by Avila to Letter Regarding Article, “Impact of Pregnancy on Mortality in Dilated Cardiomyopathy: Immediate and 12-Month Postpartum Outcomes”	26
Cardiomyopathy Across the Tree of Life: Insights for Clinicians and Investigators	25
Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay	25
Letter by Lim Regarding Article, “The Pitfalls in the World of Evidence-Based Medicine: Should IABP Be en-DANGER-ed by the Danger Shock Trial?”	25
Markets, Messaging, and Mastery: Reframing the Conversation Around the Heart Failure Physician Workforce	25
Letter by Kounis et al Regarding Article, “Biopsy-Proven Giant Cell Myocarditis Following the COVID-19 Vaccine”	24
Will the SGLT2i Responders Please Stand Up?	24
Mucopolysaccharidosis Type IIIA Presenting as Hypertrophic Cardiomyopathy	24
Air Pollution and Exposomic Impacts on Heart Failure	23
Uncovering Unrecognized Heart Failure With Preserved Ejection Fraction Among Individuals With Obesity and Dyspnea	23
PHM in Heart Transplantation: From Predicted Heart Mass to Practical Heart Matching	23
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF	23
Race, Social Determinants of Health, and Length of Stay Among Hospitalized Patients With Heart Failure: An Analysis From the Get With The Guidelines-Heart Failure Registry	23
Home-Time, Mortality, and Readmissions Among Patients Hospitalized With Heart Failure: A Baseline Prior to IMPLEMENT-HF	22
Socioeconomic Disparities Are Associated With Delayed Access to Tafamidis in Transthyretin Cardiac Amyloidosis	22
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial	22
SCAI Stage B Cardiogenic Shock: Beginning, Bad, and Broad?	22
Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality	22
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF	21

Single Arterial Access for VA-ECMO–Assisted Stenting of a Left Ventricular Assist Device Outflow Graft Obstruction in the Setting of an Oversewn Aortic Valve	21
Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure	20
Antecedent Flu-Like Illness and Onset of Idiopathic Dilated Cardiomyopathy: The DCM Precision Medicine Study	20
Ironing Out the Controversies Surrounding the Iron Deficiency Definition in Heart Failure	20
Race, Sex, and Age Disparities in the Performance of ECG Deep Learning Models Predicting Heart Failure	20
Social Determinants of Health and Heart Failure: Clinical Takeaways From 5 Pivotal Analyses of the GWTG-HF Registry	20
Response by Ezekowitz to Letter Regarding Article, “Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction”	20
Sympathetic Response to 1-Leg Cycling Exercise Predicts Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction	20
A Sweet Solution for Heart Failure With Preserved Ejection Fraction: The Role of Sodium-Glucose Cotransporter-2 Inhibitors	20
NETosis Is an Important Component of Chronic Myocardial Inflammation in Patients With Heart Failure	19
Response by Schlender et al to Letter Regarding Article, “Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support”	19
SGLT2 Inhibitor–Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event	19
Unraveling the Pathophysiological Mechanisms of Phospholamban R14del Cardiomyopathy: A Comprehensive Overview	18
Defining the Specific Skeletal Muscle Adaptations Responsible for Exercise Training Improvements in Heart Failure With Preserved Ejection Fraction	18
Transfer to Hub Hospitals and Outcomes in Cardiogenic Shock	18
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF	18
Phenomapping of Heart Failure Patients: All Clusters Are Wrong, But Are They Useful?	18
Center and Geographic Variability in Acceptance of the First Donor Heart by Race	18
Cardiorenal Syndrome: An Evolutionary Appraisal	18
Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock	17
Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin	17
Racial and Social Vulnerability Hotspots in Premature Heart Failure Mortality Across US Counties	17
Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure	17
Comparison of Blood Volume Profiles in Heart Failure With Preserved and Reduced Ejection Fractions: Sex Makes a Difference	17
Pulmonary Artery Pressure-Guided Heart Failure Management Reduces Hospitalizations in Patients With Chronic Kidney Disease	17
Harnessing the Plasma Proteome to Predict Mortality in Heart Failure Subpopulations	17
SGLT2 Inhibitors and Their Effect on Metabolism in Patients With Heart Failure	17
Patient Perceptions and Knowledge Surrounding Pregnancy After Heart Transplantation: A Multicenter Study	17
Transforming Advanced Heart Failure Programs: Addressing Institutional and Systemic Drivers of Racial and Ethnic Disparities in Care	16
Sex Differences in Skeletal Muscle Pathology in Patients With Heart Failure and Reduced Ejection Fraction	16
Response by Baudry et al to Letter Regarding Article, “Sex-Related Prognosis of VA-ECMO-Treated Cardiogenic Shock: A Post Hoc Analysis of the HYPO-ECMO Trial”	16
Single-Nuclei Transcriptomic Profiling of Human Myocardium in Long-Chain 3-Hydroxyacyl-Coenzyme A Dehydrogenase Deficiency	16
Arterial Versus Mixed Venous Lactate Levels in 1526 Cardiac Intensive Care Patients	16
Sex-Associated Differences in the Clinical Outcomes of Left Ventricular Assist Device Recipients: Insights From Interagency Registry for Mechanically Assisted Circulatory Support	16
Succinylation of SERCA2a at K352 Promotes Its Ubiquitinoylation and Degradation by Proteasomes in Sepsis-Induced Heart Dysfunction	16
Improving Fairness in the Prediction of Heart Failure Length of Stay and Mortality by Integrating Social Determinants of Health	16
Clinical Prediction Model for Antibody-Mediated Rejection: A Strategy to Minimize Surveillance Endomyocardial Biopsies After Heart Transplantation	16
Outcomes of Combined Heart and Kidney Transplantation Under the New Heart Allocation Policy: A United Organ Network for Organ Sharing Database Analysis	15
Case Implementing 2022 AHA/ACC/HFSA Guidelines: Heart Failure Management in Pregnancy: Early Planning, Close Surveillance, and Multidisciplinary Care	15
Are Men and Women That Different?	15
Simultaneous or Rapid Sequence Optimization of Medical Therapy for Heart Failure: Time to Keep Score	15
Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity	15
Acute Pulmonary Edema During Impella RP Support: Too Much of a Good Thing	15
Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure With Preserved Ejection Fraction	15
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update	15
Edge-to-Edge Transcatheter Mitral Valve Repair Versus Optimal Medical Treatment in Nonresponders to Cardiac Resynchronization Therapy: The MITRA-CRT Trial	15
Beneath the Surface: Unraveling the Proteomics of Diabetes-Related Heart Failure	15
Integrative Multiomics for Prognostic Assessment in Pulmonary Arterial Hypertension	14
Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy	14
Nitric Oxide–Mediated Coronary Endothelial Function Is Impaired in Patients With Heart Failure With Preserved Ejection Fraction	14
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction	14
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial	14
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial	14
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy	14
Trending Cardiac Biomarkers During Pregnancy in Women With Cardiovascular Disease	14
Use of a Pulmonary Artery Pressure Sensor to Manage Patients With Left Ventricular Assist Devices	13
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF	13
Neurohormonal and Renal Effects of 14-Day Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction	13
Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant	13
Early Outcomes of Heart Transplantation Using Donation After Circulatory Death Donors in the United States	13
Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease	13
Precision Medicine Is in the Eye of the Beholder	13
Response by Park et al to Letter Regarding Article, “Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to	12
Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction	12
Letter by ten Berg et al Regarding Article, “Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Regis	12
You Are Where You Eat: The Local Environment and Risk of Heart Failure	12
Letter by Shah Regarding Article, “Reversible Cause of Heart Failure?”	11
Building Resilient Clinicians: Lessons From Palliative Care Training for the Heart Failure Community	11
Combined Loss of Obsc and Obsl1 in Murine Hearts Results in Diastolic Dysfunction, Altered Metabolism, and Deregulated Mitophagy	11
Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support	11
Response by Reddy to Letter Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”	11
Letter by Sun et al Regarding Article, “Prognostic Value of Natriuretic Peptide Levels in Heart Failure With Recovered Ejection Fraction”	11
Letter by Xiong and Xie Regarding Article, “TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension”	11
From Signal to Surveillance: Assessing the Role of MicroRNAs in Cardiac Allograft Rejection	11
Response by Jentzer et al to Letters Regarding Article, “Exposure to Arterial Hyperoxia During Extracorporeal Membrane Oxygenator Support and Mortality in Patients With Cardiogenic Shock”	11
Abnormal Left Atrial Strain by CMR Is Associated With Left Heart Disease in Patients With Pulmonary Hypertension	11
Treatment With Myosin Inhibitor in a Patient With Symptomatic Hypertrophic Cardiomyopathy With Isolated Right Ventricular Obstruction	11
Impact of Heart Transplant Allocation Change on Waitlist Mortality and Posttransplant Mortality in Patients With Left Ventricular Assist Devices	11
Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Real-World Safety Study	11
Response by Glargaard et al to Letter Regarding Article, “Pleural Effusion and Invasive Hemodynamic Measurements in Advanced Heart Failure”	11

Changes in Heart Transplant Listings by Insurance and Race During the COVID Public Health Emergency	10
Iron Deficiency Induces Heart Failure With Ectopic Cardiac Calcification in Mice With Metabolic Syndrome	10
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial	10
DIGIT-HF: Results From the Win Ratio Analyses	10
Acute Heart Failure Caused by Rupture of Sinus of Valsalva Into Right Atrium in a Patient With Possible Infective Endocarditis After Tricuspid Annuloplasty: A Misdirected Clinical Decision-Making	10
Patients Who Donate Biospecimens for Research Leave a Valuable and Underappreciated Scientific Legacy	10
Myocardial DNA Damage Is Responsible for the Relationship Between Genotype and Reverse Remodeling in Patients With Dilated Cardiomyopathy	10
Pathological Analysis of T1 Pseudonormalization in the Advanced Stage of Female Fabry Cardiomyopathy	10
Significance of Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients With Negative Endomyocardial Biopsies: A Dawn of a New Era	10
Right Ventricular Function, Inflammation, and the Gut Microbiome in Pulmonary Hypertension: A Translational Frontier	10
Continuous-Flow Intra-Aortic Percutaneous Mechanical Circulatory Support in Heart Failure With Worsening Renal Function	10
Michael R. Bristow: The Consummate Physician-Scientist of This Generation	10
Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study	10
Letter by Wei et al Regarding Article, “Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin”	10
Second Wave: Dynamic LVOT Obstruction in a Patient With Previous Subaortic Membrane	10